Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

about

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

Item

http://www.wikidata.org/entity/Q42282836

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

@en

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

@nl

type

Item

label

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

@en

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

@nl

prefLabel

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

@en

Chemotherapy for advanced gastric cancer: a new milestone lies ahead.

@nl

P1476

Chemotherapy for advanced gastric cancer: a new milestone lies ahead

@en

P2093

Hiroya Takiuchi

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Disparities in gastric cancer chemotherapy between the East and West.

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

Chemotherapy for advanced gastric cancer: review of global and Japanese status.

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.

Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).

Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

P304

209-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19262712

http://www.w3.org/2001/XMLSchema#string

P932

2632534

http://www.w3.org/2001/XMLSchema#string